ZA982517B - Novel inhibitors of the formation of soluble CD23 in humans. - Google Patents

Novel inhibitors of the formation of soluble CD23 in humans.

Info

Publication number
ZA982517B
ZA982517B ZA9802517A ZA982517A ZA982517B ZA 982517 B ZA982517 B ZA 982517B ZA 9802517 A ZA9802517 A ZA 9802517A ZA 982517 A ZA982517 A ZA 982517A ZA 982517 B ZA982517 B ZA 982517B
Authority
ZA
South Africa
Prior art keywords
humans
soluble
formation
novel inhibitors
inhibitors
Prior art date
Application number
ZA9802517A
Other languages
English (en)
Inventor
Andrew Faller
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ZA982517B publication Critical patent/ZA982517B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA9802517A 1997-03-26 1998-03-25 Novel inhibitors of the formation of soluble CD23 in humans. ZA982517B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9706255.8A GB9706255D0 (en) 1997-03-26 1997-03-26 Novel compounds

Publications (1)

Publication Number Publication Date
ZA982517B true ZA982517B (en) 1999-09-27

Family

ID=10809882

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9802517A ZA982517B (en) 1997-03-26 1998-03-25 Novel inhibitors of the formation of soluble CD23 in humans.

Country Status (18)

Country Link
US (1) US6242467B1 (hu)
EP (1) EP0973732A2 (hu)
JP (1) JP2001518922A (hu)
KR (1) KR20010005627A (hu)
CN (1) CN1251091A (hu)
AR (1) AR012294A1 (hu)
AU (1) AU7210598A (hu)
BR (1) BR9808366A (hu)
CA (1) CA2285439A1 (hu)
CO (1) CO4950563A1 (hu)
GB (1) GB9706255D0 (hu)
HU (1) HUP0003021A3 (hu)
IL (1) IL131751A0 (hu)
NO (1) NO994671L (hu)
PL (1) PL336039A1 (hu)
TR (1) TR199902357T2 (hu)
WO (1) WO1998042659A2 (hu)
ZA (1) ZA982517B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904697A (en) * 1995-02-24 1999-05-18 Heartport, Inc. Devices and methods for performing a vascular anastomosis
HUP0004595A3 (en) 1997-07-31 2001-12-28 Procter & Gamble Acyclic metalloprotease inhibitors
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6566381B1 (en) 1999-03-03 2003-05-20 The Procter & Gamble Company Hetero-substituted metalloprotease inhibitors
IL145089A0 (en) 1999-03-03 2002-06-30 Procter & Gamble Alkenyl-and alkynyl-containing metalloprotease inhibitors
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20030134880A1 (en) * 2000-02-24 2003-07-17 Gordon Bruton Novel cd23 inhibitors
US20040024066A1 (en) * 2000-05-25 2004-02-05 Best Desmond John Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
DK2295081T3 (en) 2001-06-26 2019-02-18 Amgen Inc Antibodies to OPGL
WO2003037852A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
GB0128376D0 (en) * 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel compounds
WO2003056094A1 (en) * 2001-12-27 2003-07-10 Lg Electronics Inc. Washing machine
NZ536189A (en) 2002-05-29 2007-08-31 Merck & Co Inc Methylphenylsulfonyl amide derivative compounds useful in the treatment of anthrax and inhibiting lethal factor
AU2003304456A1 (en) 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
EP1747212A4 (en) 2004-05-11 2009-03-25 Merck & Co Inc PROCESS FOR PRODUCING N-SULFINATED AMINO ACID DERIVATIVES
BRPI0915762A2 (pt) * 2008-07-14 2015-11-03 Novartis Ag inibidores de mmp-12 e mmp-13 com base em ácido hidroxâmico seletivo
USD810196S1 (en) * 2015-04-14 2018-02-13 Marcia D. Fackler Sunglass book cover

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB2303850B (en) 1994-06-22 1998-06-10 British Biotech Pharm Metalloproteinase inhibitors
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
EP0757984B1 (en) 1995-08-08 2002-10-30 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives useful for inhibiting gelatinase
CN1198096A (zh) 1995-08-08 1998-11-04 菲布洛根有限公司 用于治疗与胶原蛋白过量产生有关的疾病的c-蛋白酶抑制剂
SK282863B6 (sk) * 1996-05-17 2002-12-03 Warner-Lambert Company Bifenylsulfonamidy, ich použitie a farmaceutické prostriedky na ich báze
EP0931045A1 (en) 1996-09-04 1999-07-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
HUP0003021A3 (en) 2002-02-28
GB9706255D0 (en) 1997-05-14
EP0973732A2 (en) 2000-01-26
PL336039A1 (en) 2000-06-05
CN1251091A (zh) 2000-04-19
WO1998042659A2 (en) 1998-10-01
NO994671D0 (no) 1999-09-24
AU7210598A (en) 1998-10-20
AR012294A1 (es) 2000-10-18
BR9808366A (pt) 2000-05-23
WO1998042659A3 (en) 1999-02-25
IL131751A0 (en) 2001-03-19
US6242467B1 (en) 2001-06-05
HUP0003021A2 (hu) 2002-01-28
KR20010005627A (ko) 2001-01-15
TR199902357T2 (xx) 2000-05-22
JP2001518922A (ja) 2001-10-16
CO4950563A1 (es) 2000-09-01
NO994671L (no) 1999-09-24
CA2285439A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
ZA982517B (en) Novel inhibitors of the formation of soluble CD23 in humans.
ZA98376B (en) Sulfamide-metalloprotease inhibitors
GB2346877B (en) 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
ZA200006577B (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors.
GB2321641B (en) Sulfamide-metalloprotease inhibitors
PL340727A1 (en) Benzothiazolic inhibitors of proteinous thyrosinic kinase
ZA977694B (en) Heterocyclic metalloprotease inhibitors.
ZA986594B (en) Urokinase inhibitors
HK1034609A1 (en) Dowel.
ZA9811794B (en) Ace inhibitor-MMP inhibitor combinations.
HK1039124A1 (en) Phthalzaine derivatives phosphodiesterase 4 inhibitors.
AU6882598A (en) Protein kinase inhibitor
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
GC0000142A (en) An inhibitor of the formation of soluble human cd23.
GB9815925D0 (en) HIV Intergrase inhibitors
GB9726750D0 (en) Camping aid
AU2003200717B8 (en) Cyclin-dependent kinase inhibitors and uses thereof
AU2003200717A1 (en) Cyclin-dependent kinase inhibitors and uses thereof
IL141772A0 (en) Heteroaromatic inhibitors of fructose 1,6-bisphosphatase
GB9727371D0 (en) Inhibitors
GB9725783D0 (en) Inhibitors
GB9713709D0 (en) Inhibitors
GB9709064D0 (en) Inhibitors
GB9703335D0 (en) Inhibitors
PT986382E (pt) Inibidores de raf-quinase